The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine

Rubinstein, Ethan; Predy, Gerrald; Sauvé, Laura; Hammond, Greg; Aoki, Fred Y.; Sikora, Chris; Li, Yan; Law, Barbara; Halperin, Scott A.; Scheifele, David W.

doi:10.1503/cmaj.110196

Cited by 16 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[41][42][43][44] A recently published phase 2 open-label study that includes adults older than 61 y assessed the immune response elicited after two single or two double doses of ASO3 adjuvanted H5N1 vaccine administered 21 d apart compared with unadjuvanted influenza vaccine. Two injections of a single dose of 3.75mg H5N1 ASO3 adjuvanted vaccine were shown to elicit high levels of HA and neutralizing antibodies and cell mediated immunity was maintained for six months after vaccination.…”

Section: New Vaccinesmentioning

confidence: 99%

Influenza vaccination for older adults

Talbot

Libster

Edwards

2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: New Vaccinesmentioning

confidence: 99%

Influenza vaccination for older adults

Talbot

Libster

Edwards

2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…While efforts were made to provide targeted communications to the Aboriginal population (i.e., through the Aboriginal People’s Television Network, translated radio announcements in local dialects, and a special information campaign through the Manitoba Metis Federation to its citizen membership), the impact of these efforts is unclear. To date, evaluations of pandemic H1N1 in Canada specific to Aboriginal people has concentrated on access and delivery issues in one remote area [45], case rates [16], [17], and how Aboriginal Canadians responded to the H1N1 vaccine [46].…”

Section: Introductionmentioning

confidence: 99%

Communicating Risk to Aboriginal Peoples: First Nations and Metis Responses to H1N1 Risk Messages

et al. 2013

View full text Add to dashboard Cite

Developing appropriate risk messages during challenging situations like public health outbreaks is complicated. The focus of this paper is on how First Nations and Metis people in Manitoba, Canada, responded to the public health management of pandemic H1N1, using a focus group methodology (n = 23 focus groups). Focus group conversations explored participant reactions to messaging regarding the identification of H1N1 virus risk groups, the H1N1 vaccine and how priority groups to receive the vaccine were established. To better contextualize the intentions of public health professionals, key informant interviews (n = 20) were conducted with different health decision makers (e.g., public health officials, people responsible for communications, representatives from some First Nations and Metis self-governing organizations). While risk communication practice has improved, ‘one size’ messaging campaigns do not work effectively, particularly when communicating about who is most ‘at-risk’. Public health agencies need to pay more attention to the specific socio-economic, historical and cultural contexts of First Nations and Metis citizens when planning for, communicating and managing responses associated with pandemic outbreaks to better tailor both the messages and delivery. More attention is needed to directly engage First Nations and Metis communities in the development and dissemination of risk messaging.

show abstract

“…Along with many other countries, Canada deployed a novel AS03-adjuvanted H1N1pdm09 vaccine (Arepanrix ® , GSK Canada) 2 - 5 . All Canadians older than 6 mo were eligible to receive this vaccine, which accounted for over 96% of pandemic vaccine doses administered.…”

Section: Introductionmentioning

confidence: 99%

“…The adjuvant is an oil-in-water emulsion containing squalene and tocopherol. This vaccine was used in a dose-sparing formulation (3.75 μg hemagglutinin per adult dose), one dose of which was adequately immunogenic in naïve adults 2 - 5 . By the end of the mass campaign in Canada, over 40% of the population had received this vaccine 6 .…”

Section: Introductionmentioning

confidence: 99%

Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine

Scheifele

Dionne

Ward

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Many Canadians received a novel AS03-adjuvanted vaccine during the 2009 influenza A/H1N1 pandemic. Longer term implications of adjuvant use were unclear: would anti-H1N1 immune responses persist at high levels and, if so, could that result in increased or unusual adverse effects upon re-exposure to H1N1pdm09 antigen in the trivalent influenza vaccine (TIV) for 2010–11? To answer these questions, adults given AS03-adjuvanted H1N1pdm09 vaccine (Arepanrix®, GSK Canada) 9–10 mo earlier were enrolled in an evaluator-blinded, crossover trial to receive 2010–2011 non-adjuvanted TIV (Fluviral®, GSK Canada) and placebo 10 d apart, in random order. Adverse effects were monitored for 7 d after each injection. Vaccine-attributable adverse event (VAAE) rates were calculated by subtracting rates after placebo from those after vaccine. Blood was obtained pre-vaccination and 21–30 d afterward to measure hemagglutination inhibiting antibody titers. In total, 326 participants were enrolled and 321 completed the study. VAAE rates were low except for myalgia (18.6%) and injection site pain (63.2%). At baseline, H1N1pdm09 titers ≥ 40 were present in 176/325 subjects (54.2%, 95% confidence interval 48.6, 59.7), with a geometric mean titer (GMT) of 37.4 (95% CI 32.8, 42.6). Post-immunization, 96.0% (95% CI 92.3, 97.8) had H1N1pdm09 titers ≥ 40, with GMT of 167.4 (95% CI 148.7, 188.5). Responses to both influenza A strains in TIV were similar, implying no lasting effect of adjuvant exposure. In summary, titers ≥ 40 persisted in only half the participants 9–10 mo after adjuvanted pandemic vaccine but were restored in nearly all after TIV vaccination, with minimal increase in adverse effects.

show abstract

The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine

Cited by 16 publications

References 10 publications

Influenza vaccination for older adults

Influenza vaccination for older adults

Communicating Risk to Aboriginal Peoples: First Nations and Metis Responses to H1N1 Risk Messages

Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine

Contact Info

Product

Resources

About